CareDx to Participate in Upcoming Conferences
09/02/2021 - 07:00 AM
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced today the Company plans to participate in the 2021 Wells Fargo Healthcare Conference and H.C. Wainwright 23rd Annual Global Investment Conference.
CareDx’s management will be participating in the 2021 Wells Fargo Healthcare Conference on Thursday, September 9, 2021 at 3:20 p.m Eastern Time. To listen to a live webcast, please visit the investor relations section of CareDx’s website at: investors.caredxinc.com .
CareDx’s management will be participating in the H.C. Wainwright 23rd Annual Global Investment Conference with a presentation available on Monday, September 13, 2021 at 7:00 a.m Eastern Time. To listen to the webcast, please visit the investor relations section of CareDx’s website at: investors.caredxinc.com .
About CareDx www.CareDx.com .
CONTACTS: sking@caredx.com
Investor Relationsinvestor@caredx.com
CDNA Rankings
#5231 Ranked by Stock Gains
CDNA Stock Data
Industry
Medical Laboratories
Sector
Health Care and Social Assistance
Tags
Health Technology, Medical Specialties, Health Care and Social Assistance, Medical Laboratories
Country
US
City
South San Francisco
About CDNA
caredx: transforming transplant patient care through novel surveillance management solutions caredx, inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics. by combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, caredx is at the forefront of organ transplant surveillance and pre-transplant hla typing solutions. nasdaq:cdna about allosure® allosure is the first and only non-invasive blood test that directly measures allograft injury and identifies the probability of active rejection to better manage kidney transplant patients. allosure is a clinical-grade, proprietary next-generation sequencing (ngs) based test to detect donor-derived cell-free dna (dd-cfdna) in order to identify organ injury in kidney transplant recipients. allosure is analytically validated as a sensitive, specific, and precise measurement of dd-cfdna. allos
